Turner JA, Ciol MA, Von Korff M, Rothman I, Berger RE (2004) Healthcare use and costs of primary and secondary care patients with prostatitis. Urology 63(6):1031–1035

Article  PubMed  Google Scholar 

Bouiller K, Zayet S, Lalloz PE, Potron A, Gendrin V, Chirouze C et al (2022) Efficacy and safety of oral Fosfomycin-Trometamol in male urinary tract infections with Multidrug-Resistant enterobacterales. Antibiot Basel Switz.;11(2)

Krieger JN, Nyberg J, Leroy, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282(3):236–237

Article  CAS  PubMed  Google Scholar 

Kwan ACF, Beahm NP (2020) Fosfomycin for bacterial prostatitis: a review. Int J Antimicrob Agents 56(4):106106

Article  CAS  PubMed  Google Scholar 

Mazzoli S (2007) Conventional bacteriology in prostatitis patients: Microbiological bias, problems and epidemiology on 1686 microbial isolates. Arch Ital Urol Androl Organo Uff Soc Ital Ecogr Urol E Nefrol 79(2):71–75

Google Scholar 

Grayson ML, Macesic N, Trevillyan J, Ellis AG, Zeglinski PT, Hewitt NH et al (2015) Fosfomycin for treatment of prostatitis: new tricks for old dogs. Clin Infect Dis 61(7):1141–1143

Article  CAS  PubMed  Google Scholar 

Lipsky BA, Byren I, Hoey CT (2010) Treatment of bacterial prostatitis. Clin Infect Dis Off Publ Infect Dis Soc Am 50(12):1641–1652

Article  Google Scholar 

Marquez-Algaba E, Pigrau C, Bosch-Nicolau P, Viñado B, Serra-Pladevall J, Almirante B et al (2021) Risk factors for relapse in acute bacterial prostatitis: the impact of antibiotic regimens. Microbiol Spectr 9(2):e00534–e00521

Zhanel GG, Zhanel MA, Karlowsky JA (2018) Oral fosfomycin for the treatment of acute and chronic bacterial prostatitis caused by Multidrug-Resistant Escherichia coli. Can J Infect Dis Med Microbiol J Can Mal Infect Microbiol Medicale 2018:1404813

Google Scholar 

Charalabopoulos K, Karachalios G, Baltogiannis D, Charalabopoulos A, Giannakopoulos X, Sofikitis N (2003) Penetration of antimicrobial agents into the prostate. Chemotherapy 49(6):269–279

Article  CAS  PubMed  Google Scholar 

Marino A, Stracquadanio S, Bellanca CM, Augello E, Ceccarelli M, Cantarella G et al (2022) Oral fosfomycin formulation in bacterial prostatitis: new role for an old Molecule-Brief literature review and clinical considerations. Infect Dis Rep 14(4):621–634

Article  PubMed  PubMed Central  Google Scholar 

Dubey S, Siddiqui AH, Sharma M (2024) The impact of fosfomycin on gram negative infections: A comprehensive review. Indian J Microbiol 64(3):846–858

Article  PubMed  Google Scholar 

Raz R (2012) Fosfomycin: an old—new antibiotic. Clin Microbiol Infect 18(1):4–7

Article  CAS  PubMed  Google Scholar 

Liu P, Chen S, Wu Z, ying, Qi M, Li X, yang, Liu C (2020) xia. Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist.;22:238–43

Wang YP, Chen YH, Hung IC, Chu PH, Chang YH, Lin YT et al (2022) Transporter genes and FosA associated with fosfomycin resistance in Carbapenem-Resistant Klebsiella pneumoniae. Front Microbiol 13:816806

Article  PubMed  PubMed Central  Google Scholar 

Gardiner BJ, Mahony AA, Ellis AG, Lawrentschuk N, Bolton DM, Zeglinski PT et al (2014) Is fosfomycin a potential treatment alternative for multidrug-resistant gram-negative prostatitis? Clin Infect Dis Off Publ Infect Dis Soc Am 58(4):e101–105

Article  CAS  Google Scholar 

Aggarwal N, Leslie SW, Lotfollahzadeh S Recurrent Urinary Tract Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Nov 11]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK557479/

Cai T (2021) Recurrent uncomplicated urinary tract infections: definitions and risk factors. GMS Infect Dis 9Doc03 [Internet]. May 27 [cited 2024 Nov 11]; Available from: https://www.egms.de/en/journals/id/2021-9/id000072.shtml

Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM et al (2005) Infectious diseases society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis Off Publ Infect Dis Soc Am 40(5):643–654

Article  Google Scholar 

The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 15.0 (2025) https://www.eucast.org[Internet]. [cited 2025 Jan 13]. Available from: https://www.eucast.org/clinical_breakpoints

Downs SH, Black N (1998) The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health 52(6):377–384

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haddaway NR, Page MJ, Pritchard CC, McGuinness LA (2022) PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev 18(2):e1230

Article  PubMed  PubMed Central  Google Scholar 

Cai T, Tamanini I, Mattevi D, Verze P, Palmieri A, Malossini G et al (2020) Fosfomycin Trometamol and N-acetyl-L-cysteine as combined oral therapy of difficult-to-treat chronic bacterial prostatitis: results of a pilot study. Int J Antimicrob Agents 56(1):105935

Article  CAS  PubMed  Google Scholar 

Burgos J, Hoyos-Mallecot Y, Ferre-Losa C, Arando M, Monforte A, Pumarola T et al (2023) Oral fosfomycin for treatment of acute bacterial prostatitis caused by multidrug-resistant enterobacterales. Microbiol Spectr 11(5):e0213623

Article  PubMed  Google Scholar 

Karaiskos I, Galani L, Sakka V, Gkoufa A, Sopilidis O, Chalikopoulos D et al (2019) Oral fosfomycin for the treatment of chronic bacterial prostatitis. J Antimicrob Chemother 74(5):1430–1437

Article  CAS  PubMed  PubMed Central  Google Scholar 

Los-Arcos I, Pigrau C, Rodríguez-Pardo D, Fernández-Hidalgo N, Andreu A, Larrosa N et al (2016) Long-term fosfomycin-tromethamine oral therapy for difficult-to-treat chronic bacterial prostatitis. Antimicrob Agents Chemother 60(3):1854–1858

Article  CAS  PubMed Central  Google Scholar 

Fukushima S, Otsuka Y, Hagiya H, Nishikawa N, Otsuka F (2024) Prostate abscess caused by ESBL-producing Escherichia coli successfully treated with fosfomycin monotherapy. Int J Antimicrob Agents 63(6):107182

Article  CAS  PubMed  Google Scholar 

Denes E (2021) Prolonged course of Fosfomycin-Trometamol for chronic prostatitis: an unknown good option. Scand J Urol 55(4):344–345

Article  CAS  PubMed  Google Scholar 

Gian J, Cunha BA (2016) Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: successful treatment with prolonged fosfomycin therapy. Int J Antimicrob Agents 47(5):414

Article  CAS  PubMed  Google Scholar 

Cunha BA, Gran A, Raza M (2015) Persistent extended-spectrum β-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and Doxycycline. Int J Antimicrob Agents 45(4):427–429

Article  CAS  PubMed  Google Scholar 

Hagiya H, Ninagawa M, Hasegawa K, Terasaka T, Kimura K, Waseda K et al (2014) Fosfomycin for the treatment of prostate infection. Intern Med Tokyo Jpn 53(22):2643–2646

Article  Google Scholar 

Dubos M, Barraud O, Fedou AL, Fredon F, Laurent F, Brakbi Y et al (2014) Prostatic abscesses and severe sepsis due to methicillin-susceptible Staphylococcus aureus producing Panton-Valentine leukocidin. BMC Infect Dis 14:466

Article  PubMed  PubMed Central  Google Scholar 

Peirano G, Ahmed-Bentley J, Woodford N, Pitout JD (2011) New Delhi metallo-beta-lactamase from traveler returning to Canada. Emerg Infect Dis 17(2):242–244

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerin F, Henegar C, Spiridon G, Launay O, Salmon-Ceron D, Poyart C (2005) Bacterial prostatitis due to Pseudomonas aeruginosa harbouring the blaVIM-2 metallo--lactamase gene from Saudi Arabia. J Antimicrob Chemother 56(3):601–602

Article  CAS  PubMed  Google Scholar 

Almeida F, Santos Silva A, Silva Pinto A, Sarmento A (2019) Chronic prostatitis caused by extended-spectrum β-lactamase-producing Escherichia coli managed using oral fosfomycin-A case report. IDCases 15:e00493

Article  PubMed  PubMed Central  Google Scholar 

Tang M, Ip WCT, Yuen JKY, Shea YF (2023) Chronic prostatitis with recurrent extended-spectrum beta-lactamase–producing Escherichia coli bacteraemia treated with prolonged fosfomycin. Hong Kong Med J 29(4):358.e1-358.e2

Google Scholar 

Veve MP, Wagner JL, Kenney RM, Grunwald JL, Davis SL (2016) Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections. Int J Antimicrob Agents 48(1):56–60

Article  CAS  PubMed